PMID- 18271924
OWN - NLM
STAT- MEDLINE
DCOM- 20080422
LR  - 20161124
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Linking)
VI  - 99
IP  - 2
DP  - 2008 Feb
TI  - Expression of glucose transporters and hexokinase II in cholangiocellular 
      carcinoma compared using [18F]-2-fluro-2-deoxy-D-glucose positron emission 
      tomography.
PG  - 260-6
LID - 10.1111/j.1349-7006.2007.00683.x [doi]
AB  - Cholangiocellular carcinoma (CCC) has been reported to have a high glucose 
      uptake; however, the mechanism of glucose entry into these cells is still 
      unclear. We investigated the relationship between 
      [(18)F]-2-fluro-2-deoxy-D-glucose ((18)F-FDG) uptake and the expression of 
      facilitative glucose transporters (Glut) and hexokinase (HK) II, as well as the 
      association between the expression of different histological types of CCC. The 
      expression of Glut (1-5) and HK II was studied using immunohistochemistry of 26 
      patients with CCC who underwent whole-body (18)F-FDG positron emission tomography 
      before surgery or biopsy. CCC expressed immunohistochemically detectable Glut 1 
      in 81%, Glut 2 in 54%, Glut 3 in 19%, and HK II in 77% of the total cases. Glut 
      1, Glut 2, Glut 3, and HK II were more often detected in moderately 
      differentiated and poorly differentiated than in well-differentiated CCC. A 
      significant correlation was observed between (18)F-FDG uptake and the staining 
      scores of Glut 1 and HK II (P = 0.02, rho = 0.45 and P = 0.001, rho = 0.59). The 
      staining scores of Glut 1 and HK II were also significantly correlated (P = 
      0.002, rho = 0.3). Multivariate regression analysis revealed that lymph-node 
      metastasis was independently associated with (18)F-FDG uptake. Our study showed a 
      significant association between the expression of Glut 1 and HK II with (18)F-FDG 
      uptake, indicating that Glut 1 is a major glucose transporter expressed in CCC 
      and that HK II contributes to the increased metabolism of glucose, especially in 
      moderately and poorly differentiated CCC.
FAU - Paudyal, Bishnuhari
AU  - Paudyal B
AD  - Department of Diagnostic Radiology and Nuclear Medicine, Gunma University 
      Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, 
      Japan. paudyal@med.gunma-u.ac.jp
FAU - Oriuchi, Noboru
AU  - Oriuchi N
FAU - Paudyal, Pramila
AU  - Paudyal P
FAU - Higuchi, Tetsuya
AU  - Higuchi T
FAU - Nakajima, Takashi
AU  - Nakajima T
FAU - Endo, Keigo
AU  - Endo K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Glucose Transport Proteins, Facilitative)
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - EC 2.7.1.1 (Hexokinase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Bile Duct Neoplasms/diagnostic imaging/enzymology/*metabolism
MH  - *Bile Ducts, Intrahepatic
MH  - Cholangiocarcinoma/diagnostic imaging/enzymology/*metabolism
MH  - Female
MH  - Fluorodeoxyglucose F18/*pharmacokinetics
MH  - Glucose Transport Proteins, Facilitative/*metabolism
MH  - Hexokinase/*metabolism
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Middle Aged
MH  - *Positron-Emission Tomography
MH  - Radiopharmaceuticals/*pharmacokinetics
EDAT- 2008/02/15 09:00
MHDA- 2008/04/23 09:00
CRDT- 2008/02/15 09:00
PHST- 2008/02/15 09:00 [pubmed]
PHST- 2008/04/23 09:00 [medline]
PHST- 2008/02/15 09:00 [entrez]
AID - CAS683 [pii]
AID - 10.1111/j.1349-7006.2007.00683.x [doi]
PST - ppublish
SO  - Cancer Sci. 2008 Feb;99(2):260-6. doi: 10.1111/j.1349-7006.2007.00683.x.